Doug Godfrin, PhD - VeraMorph

Why Sal Is Bullish on Biotech

VeraMorph has a new way to deliver insoluble drugs by mouth. Founder Doug Godfrin, PhD elucidates the promise of accessing the 85% of drugs that are not soluble. Does VeraMorph pass Sal Daher’s screen for angel-scale biotech? Listen and find out.

Sponsors: Purdue University entrepreneurship and Peter Fasse, patent attorney at Fish and Richardson

Highlights:

• Sal Daher, CFA Introduces Doug Godfrin, PhD, Founder of VeraMorph
• A New Way to Deliver Drugs Orally
• How VeraMorph Gets Around the Solubility Problem
• VeraMorph’s Approach Is Janus-like: Shelf Stable but Available Where Needed
• The Decade of Biotech & VeraMorph
• AltrixBio: Gastric Bypass Surgery in a Pill
• Sal Daher’s Biotech Screen: Strong Patents
• “VeraMorph actually owns the patents outright for this platform technology.”
• “We've really taken a totally different perspective with this class of material by focusing on immediate release via oral delivery...”
• Sal Daher’s Biotech Screen: Capable Academic Founder
• Sal Daher’s Biotech Screen: Is it Angel-Scale?
• US$1 Million Will Get VeraMorph to Production for Pre-Clinical Trials
• “...chances of reaching that next set of milestones is 90% or above.”
• Doug Godfrin Is Collaborating with Colin Minchom, PhD, a Veteran of Drug Development
• US$ 2 to 3 million More Will Take VeraMorph to Clinical Stage, Doug Predicts
• Sal and Doug Look at the Odds of Getting to Clinical Stage
• Sal Daher’s Biotech Screen: Do Strategics Care?
• Sal Daher’s Biotech Screen: Platform Technology?
• Sponsors Purdue University and Peter Fasse Are Founder-Friendly
• The Upside of Failure in Biotech
• This guy calls me up, "Saleh, let's get together at Darwin's in Cambridge. I want to talk to you about a new company."
• Doug Godfrin’s Parting Thoughts

Topics: biotech